Download presentation
Presentation is loading. Please wait.
Published byAllison Morrow Modified over 10 years ago
1
FUNGAL KERATITIS IN MAN Andrew Tullo Royal Eye Hospital, Manchester
4
INCIDENCE OF FUNGAL KERATITIS (FK) Developed world 6 -35% of all microbial keratitis Developing world 22 - >50% Thomas PA Eye 2003;7:852
5
FUNGAL GROUPS Filamentous - Aspergillus - Fusarium - Dematiaceous Yeasts - Candida Garg et al Cornea 2004;23:571
6
DISTRIBUTION (%)
7
FACTORS IN PATHOGENESIS Injury, ocular surface compromise Temperature Wind Humidity Urbanisation/employment
11
DIAGNOSIS Clinical features (diff.diagnosis) Microbiology Histopathology DNA amplification
14
ASPERGILLUS AND CORNEAL FOREIGN BODY 3 cases Medical cure (1), surgical cure (2) All required hospitalisation All had lasting visual impairment Fahad et al Br J Ophthalmol 2004;88:847
17
DIAGNOSIS Clinical features Microbiology Histopathology DNA amplification
18
DIAGNOSIS Clinical features Microbiology Histopathology DNA amplification
19
HISTOPATHOLGY Haematoxylin and eosin (H&E) Periodic acid-Schiff (PAS) Grocott
21
DIAGNOSIS Clinical features Microbiology Histopathology DNA amplification Gaudio et al Br J Ophthalmol 2002;86:755
22
OPTIMAL MANAGEMENT 1 low threshold of suspicion biopsy even when scrape is negative appropriate topical therapy ?intracameral injection Kaushik et al Cornea 2001;20:715
23
ANTIFUNGAL AGENTS 1 Natamycin Amphotericin B Flucytosine Azoles
24
AZOLES Clotrimazole Miconazole Econazole Ketoconazole Itraconazole Fluconazole Voriconazole?
25
OPTIMAL MANAGEMENT 2 avoidance of topical steroid? early surgery (up to 30%) systemic medication
28
OUTCOME Severity - delay in diagnosis - genus of fungus Treatment - compliance - toxicity - availability
33
CONCLUSION FK rare in UK but ?increasing Outcome dictated by diagnosis, species and management Optimal treatment may include surgery, better medication and intracameral injection
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.